The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
about
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseInterstitial lung disease: progress and problemsElderly patients and inflammatory bowel diseaseAssessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative dataInfliximab-Related Infusion Reactions: Systematic ReviewCurrent therapy of pediatric Crohn's diseaseA new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UCA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabReview article: Infliximab therapy for inflammatory bowel disease--seven years onA multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyLost in translation: helping patients understand the risks of inflammatory bowel disease therapy.Inflammatory bowel disease: perioperative pharmacological considerations.Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.A rare case of supraventricular tachycardia induced by Infliximab: a case report.Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysisEfficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experiencePatient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease.Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Are adult patients more tolerant of treatment risks than parents of juvenile patients?Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease.The safety of infliximab infusions in the community settingPreventing infective complications in inflammatory bowel disease.Patient preferences for surgical versus medical therapy for ulcerative colitis.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentUpdate on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Vaccinations in patients with immune-mediated inflammatory diseasesCurrent status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.Pulmonary manifestations of inflammatory bowel diseaseVedolizumab for Crohn's disease.Pulmonary manifestations of Crohn's disease.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseAppropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Infliximab and ulcerative colitis.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept.
P2860
Q24188040-9123820B-10F0-4F87-A27D-8E94709B42DAQ24655716-D2CA2B3C-2CF9-43E2-A023-128D0E803400Q26768270-8112BC4D-2D9D-4059-978A-58161FF3A60EQ26864906-6D9606F8-6BD9-4E64-BDE9-AD8B1D4A86E6Q27013835-F299A9CC-AE20-4038-9A40-78DDFCB08A1AQ28081919-412164F4-3554-4111-A455-427C5377660DQ28248835-CE385059-2441-4296-9D59-016AC65C0CEAQ28282330-91F32F75-C0DA-4817-9C1C-9A7DBAA58F8BQ28294134-05E19FCE-8C94-48AB-AE24-D6482B1E2C77Q30430605-ADC56CDF-4992-4E44-A795-F5515DB7214CQ30498145-2608D0B8-A7A8-4D0F-8C7D-7E6A6543F9BDQ30502980-59D1F25C-B3FB-4413-92DB-4018CDA5C563Q30571620-6AB1B79A-6287-4860-96BF-680E0A1E7865Q33157116-5A450B8F-EC08-4371-A714-E86BC3200DB9Q33158097-895D7FEE-DDCE-41A3-A49C-7BB6DE927C7DQ33564492-067A7224-B50A-4C3E-AEA9-49A8755098D9Q33573112-4D29740C-824E-406D-83B1-418C9FE4E56BQ33626027-D88B555D-204A-4146-948E-1845D5034772Q33626895-22303459-DF89-4751-8CD9-072D1A38A373Q33750759-FFFEC7A8-E62E-4EDF-88E9-11C9CDCA837EQ33756924-36BA1609-DBCE-4402-8CCB-BCA294E313CCQ33756929-2AE1CD19-7D0F-476C-AD30-AA3CEBCBABB7Q33761151-846EB3E3-54FD-491A-8D60-E999FD35EDDFQ33869073-535DD4FB-CBD9-47BF-9B87-1620C1D5B66FQ33916750-E690DF07-F51D-4FC1-88FF-4FBFA93E5371Q34008766-69DAA044-9D44-4DB5-9201-1EA49BEBB5B7Q34065549-0160160B-B926-411E-AA3B-513B76B935DDQ34073191-F5F584C6-91FF-490A-BAD8-2655D79BE409Q34078707-B1D3303E-1E7D-4A73-B0A2-A4C115BB6EB9Q34117134-22C0FD6A-D501-4484-97FF-9FCB2BCC1330Q34127277-95A5EE2C-1BFA-413C-A703-CDB20CBDEACFQ34225622-135C4595-DFA3-422A-9CC5-A5F821FCAE08Q34303009-FD12D8C5-19B8-4D3C-A41C-3B43C2D0AB89Q34326912-A7C43848-A392-4472-A286-F5567F2F7773Q34397357-D48044EF-82BE-4E80-B92D-A8BD773D08BDQ34449843-BF8BD7D6-0E1F-4223-85B2-6DA1A08241AEQ34476049-0BB18145-7247-48A1-B24D-88E9D1C3F9F1Q34503548-F619C928-6205-4FA5-966B-87CBCCD591F3Q34564902-8C645FED-83C4-47F5-A199-DBB931C18781Q34607722-AF56DFD0-04E6-43A5-A24D-B9C693C0E8E0
P2860
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The safety profile of inflixim ...... ic experience in 500 patients.
@ast
The safety profile of inflixim ...... ic experience in 500 patients.
@en
The safety profile of inflixim ...... ic experience in 500 patients.
@nl
type
label
The safety profile of inflixim ...... ic experience in 500 patients.
@ast
The safety profile of inflixim ...... ic experience in 500 patients.
@en
The safety profile of inflixim ...... ic experience in 500 patients.
@nl
prefLabel
The safety profile of inflixim ...... ic experience in 500 patients.
@ast
The safety profile of inflixim ...... ic experience in 500 patients.
@en
The safety profile of inflixim ...... ic experience in 500 patients.
@nl
P2093
P50
P1433
P1476
The safety profile of inflixim ...... ic experience in 500 patients.
@en
P2093
Cathy D Schleck
Laurence J Egan
W Scott Harmsen
P356
10.1053/J.GASTRO.2003.10.047
P407
P50
P577
2004-01-01T00:00:00Z